Healthcare Triangle Inc

This management proposal asks shareholders to approve an amendment to the Company’s 2020 Stock Incentive Plan that would cause the plan’s reserved share pool to increase automatically on the first day of each fiscal year beginning in 2026. The automatic increase would be the greater of three alternatives (fixed 2,000,000 shares; 20% of outstanding common shares as of the prior fiscal year-end; or an Administrator-determined amount), and the amendment would expire with the Plan on December 31, 2030. Management frames the change as necessary to maintain competitive compensation for employees, directors and consultants—arguing that without automatic replenishment the Company may need special meetings or risk losing talent while awaiting shareholder approval. The proposal therefore addresses operational flexibility and recruiting/retention risk, particularly relevant for a growth-stage company pursuing acquisitions and financings. Opposing views (and proxy advisory concerns) would focus on shareholder dilution, erosion of shareholder control over equity compensation and potential excessive share issuance without direct annual shareholder consent. The Board’s recommendation for approval is based on anticipated future hiring, compensation needs, and administrative efficiency; it acknowledges dilution but presents the amendment as aligned with long-term shareholder value creation through talent alignment. For governance-conscious investors, material safeguards to monitor overhang will include disclosure of annual awards, burn rates and Administrator grant practices; the plan’s termination date and existing Section 10 adjustment provisions are modest limiting factors. Overall, the proposal increases management flexibility on equity grants, trading off increased dilution risk and reduced shareholder oversight for speed and cost-efficiency in compensation administration.

This management proposal seeks pre-approval under Nasdaq Rule 5635(d) for potential future transactions that could constitute a 20% Issuance sold below the Minimum Price, by setting fixed, non-amendable parameters (caps on shares, warrant exercises, aggregate dollars, max discount, purpose and a three-month completion window). Management argues approval preserves flexibility to raise up to $100 million or issue large share volumes in a short timeframe to provide working capital or respond to strategic opportunities while satisfying Nasdaq’s pre-approval requirement. The disclosed Nasdaq Parameters are broad (up to 250 million shares and 80% maximum discount), representing significant potential dilution and pricing flexibility; the three-month time frame limits the period of authority but still permits large near-term financings. The Board frames this as a pro-liquidity, operationally necessary measure for a company engaged in acquisitions and other financings; but for investors, the breadth of share and discount caps is concerning and increases the risk of rapid, deep-dilutive financings. Governance-minded investors will evaluate whether the parameters are appropriately constrained and whether the Company will provide follow-up disclosures on any issuances, including use of proceeds and impact on capitalization. The management recommendation to approve rests on the assertion that these steps are required to preserve Nasdaq listing and execute on near-term working capital needs; opposition would emphasize shareholder dilution and potential opportunistic issuance at steep discounts. The proposal therefore represents a tradeoff between quick access to capital under Nasdaq-compliant authorization and meaningful dilution risk that could materially affect existing holders' voting power and economic interests.

This proposal requests shareholder approval to issue 2,828,167 common shares to Blockedge Technologies Inc. (a SecureKloud subsidiary) as settlement consideration related to the Company’s 2024 asset acquisition from SecureKloud. The issuance is required to effect the agreed cancellation of Series B Preferred Stock that originally represented a much larger pre-reverse-split common share equivalent, and Nasdaq Rule 5635(a) mandates shareholder approval because the original deal contemplated a share issuance above Nasdaq’s 20% threshold. Management presents the issuance as a contractual obligation necessary to honor acquisition consideration and complete the accounting and ownership adjustments arising from the reverse splits and the Settlement Agreement. Opposing concerns focus on the magnitude of dilution represented by the Settlement Shares relative to the Company’s modest outstanding base (the filing explicitly warns of substantial dilution to existing holders). The Board recommends approval to satisfy the Company’s obligations and avoid breach or litigation risk, but stockholders should weigh the dilution against the strategic value of the acquired assets and any synergies realized to date. Investors should also evaluate the historical valuations, the asset integration progress, and whether the economic benefit of the acquisition justifies the dilution. From a governance standpoint, this is a transactional, not governance-driven, vote—its evaluation centers on deal economics, precedent, and the potential operational benefit of SecureKloud assets versus the immediate dilutive impact on shareholders.

This proposal asks shareholders to authorize issuance of securities needed to satisfy the consideration for the Company’s acquisition of Teyame 360 S.L. and Datono Mediacion S.L., a transaction with an aggregate potential purchase price of roughly $50 million comprised of cash and a mix of common and non-voting convertible preferred stock, including a management earnout tied to performance. Nasdaq Rule 5635(a) requires shareholder approval because the securities issuable (or issuable upon conversion) exceed the 20% threshold of outstanding shares; without approval the Company may be unable to consummate the deal on agreed terms. Management argues the acquisition is strategically important to position the Company as a global AI digital-health provider and that the mix of equity and cash consideration conserves cash while aligning sellers’ incentives with the Company’s success. From a shareholder perspective the key tradeoffs are sizable dilution and governance implications of issuing large amounts of common and preferred stock versus the potential revenue, technology and market expansion benefits. Investors should assess the purchase price relative to the targets’ revenue, profitability, integration risk, and whether the Company can realize synergies sufficient to offset dilution. The Board’s recommendation to approve reflects belief that the transaction accelerates strategic growth; critics will want robust disclosure on post-closing integration milestones, sensitivity to conversion mechanics of convertible preferreds, and contingency plans if milestones are missed. Approval would permit the Company to issue up to the disclosed amounts and proceed with planned payments; rejection would likely prevent the transaction closing as structured and force renegotiation or termination. In sum, this is a high-impact financing-and-acquisition vote where shareholders must balance near-term dilution against potential long-term value creation from the Teyame assets.

This management proposal requests shareholder approval under Nasdaq Rule 5635(d) to permit issuance of common shares in excess of the Exchange Cap established under the ELOC Purchase Agreement with Hudson Global, enabling the Company to draw from a potential $50 million equity line over a 36-month period. The ELOC as structured gives the Company unilateral control over timing and amounts of sales (subject to per-day and valuation caps) while Hudson Global is obligated to purchase directed amounts; the Exchange Cap equals roughly 405,354 shares (≈19.99% pre-transaction), and approval would remove that ceiling. The financing provides flexibility to raise working capital and supports operations but presents dilution risk, potential share sales at discounted prices (pricing mechanics allow prices at a discount to market), and the possibility of large near-term share issuance depending on management’s funding choices. The issuance of a 50,000-share warrant as a commitment fee introduces additional potential dilution and complexity; it contains cashless exercise and a 4.99% ownership limitation but is still economically meaningful. Board rationale emphasizes access to committed capital and optionality in capital planning; investor concerns center on governance, signaling, and the potential for depressed share prices if significant supply enters the market. Accepting the proposal effectively prioritizes access to flexible capital over preserving a strict anti-dilution ceiling, and shareholders should weigh the Company’s near-term liquidity needs, alternative funding sources, and mitigation measures (e.g., disclosure, usage of proceeds, and rotation of sales) when evaluating the authorization. The Company’s described limitations and registration obligations partially mitigate but do not eliminate the dilution and market impact risk inherent in the ELOC structure.

This proposal seeks shareholder approval to permit potential conversion of the Company’s June 12, 2026 OID senior secured convertible debentures into common stock under Nasdaq Rules 5635(b) and 5635(d), because conversion could result in issuance of approximately 9.37 million shares—exceeding the 20% threshold relative to the Company’s ~2.03 million outstanding shares. The debentures carry a Floor Price of $0.452 and a conversion metric of the greater of the Floor or 85% of a recent low-VWAP, introducing potential for conversion at steep discounts relative to prevailing market prices; maturity and extension mechanics, prepayment penalties and a requirement to prepay 25% of net proceeds from future financings add financial complexity. Management recommends approval to preserve access to the secured financing and to comply with Nasdaq pre-approval obligations so conversion mechanics can proceed without rule-driven impediments. For investors, the core concerns are the significant dilution implied by full conversion, the potential downward pressure on share price from conversions at discounted prices, and the senior secured nature of the debentures which may affect creditor priority and future capital structure. The Board emphasizes the use of proceeds for working capital and repayment of existing notes, framing the financing as necessary for near-term liquidity; shareholders must balance that immediate need against long-term equity dilution and governance consequences. Evaluating this proposal requires reviewing the terms of the debentures, alternative financing options, covenant protections, and the Company’s cash runway—if alternative non-dilutive capital is available, shareholders may prefer that pathway. Ultimately, the vote authorizes a high-dilution conversion pathway intended to secure additional capital but material to the Company’s capitalization and control profile if conversions occur.

This management proposal requests authority to adjourn or postpone the Annual Meeting if there are insufficient votes to approve one or more of the substantive proposals, enabling the Board to solicit further proxies and potentially achieve the votes they consider necessary. Management argues this power preserves shareholder value by avoiding rushed decisions and permitting additional outreach; it is a routine procedural safety valve commonly proposed when multiple non-routine, dilutive proposals are on the ballot. From a governance perspective, the adjournment authorization centralizes discretion with the named proxies and board to extend the meeting period—some investors may see this as appropriate practical flexibility, while others may view it as an instrument that could be used to manipulate timing to secure desired outcomes. The scope of the adjournment authority is limited to additional solicitation of votes and does not change the substance of the underlying proposals, but its exercise could delay finality for investors. The Board’s recommendation to approve is consistent with enabling orderly meeting conduct and maximizing stockholder participation. Shareholders should consider whether they are comfortable with the board’s discretion to delay the vote and whether adequate transparency will accompany any adjournment actions (e.g., updated disclosure of solicitation efforts and revised meeting dates). In sum, this is a procedural proposal that reduces the risk of failing to consummate transactions due to temporary shortfalls in support, but it confers practical tactical flexibility to the Board that investors should monitor.